1. Home
  2. KRKR vs RNAZ Comparison

KRKR vs RNAZ Comparison

Compare KRKR & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 36Kr Holdings Inc.

KRKR

36Kr Holdings Inc.

HOLD

Current Price

$4.13

Market Cap

9.2M

ML Signal

HOLD

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$9.36

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRKR
RNAZ
Founded
2010
2016
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
8.5M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
KRKR
RNAZ
Price
$4.13
$9.36
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$280.00
AVG Volume (30 Days)
2.3K
12.8K
Earning Date
09-26-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$30,966,526.00
N/A
Revenue This Year
$182.55
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.90
$6.15
52 Week High
$21.36
$468.44

Technical Indicators

Market Signals
Indicator
KRKR
RNAZ
Relative Strength Index (RSI) 32.63 49.02
Support Level $4.25 $8.20
Resistance Level $4.80 $11.28
Average True Range (ATR) 0.24 0.59
MACD -0.02 0.21
Stochastic Oscillator 2.12 37.69

Price Performance

Historical Comparison
KRKR
RNAZ

About KRKR 36Kr Holdings Inc.

36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Share on Social Networks: